mRNA Synthesis Raw Materials 2024 Industry - Technologies, Applications, Verticals, Strategies & Forecast 2030

 

mRNA Synthesis Raw Materials Industry Overview

The global mRNA synthesis raw materials market size was estimated at USD 1.72 billion in 2023 and is anticipated to grow at a CAGR of 2.85% from 2024 to 2030.

mRNA is synthesized by the process of transcription in the nucleus by using a template made up of a DNA nucleotide sequence. It includes various steps such as initiation, elongation, editing, and termination. mRNA synthesis has a broad range of applications in drug discovery, vaccine development, and the manufacturing of therapeutics. RNA-based vaccines have better immunogenicity, higher efficiency, and require short production time. The key factors driving the market growth include the growing academic and industrial interest in mRNA technology, the advantages of mRNA vaccines, and increasing funding for research.

Gather more insights about the market drivers, restrains and growth of the mRNA Synthesis Raw Materials Market

The COVID-19 pandemic created new opportunities for mRNA technology platforms with the introduction and widespread use of vaccines. Government agencies from several nations, research institutions, and numerous biotech and pharmaceutical companies are focusing on efficient and quick methods for the rapid detection of COVID-19. mRNA vaccines are a safe and efficient method for preventing COVID-19. In addition, the advantages associated with the mRNA-based COVID-19 vaccines have sparked the attention of pharmaceutical businesses in delivering vaccines swiftly across the globe.

The National Institute of Allergy & Infectious Diseases and Moderna, Inc. mutually developed the mRNA-1273 (NIAID) in March 2020. It shows 94.1% efficacy in symptomatic prevention from COVID-19 and in December 2020, received emergency use authorization from the US Food & Drug Administration (US FDA) for widespread immunization of people. As a result, the usage of mRNA vaccines increased exponentially during the COVID-19 pandemic.

Recently, RNA centers have been established at numerous institutions to promote therapeutic uses of RNA, particularly in vitro transcribed (IVT) mRNA. These facilities include the Yale Center for RNA Science and Medicine, the RNA Institute at the University of Albany, the State University of New York, and the RNA Therapeutic Institute at the University of Massachusetts in the United States. Additionally, university spin-off businesses funded by significant venture capital infusions such as Argos Medicines, Factor Bioscience, CureVac, Ethris, BioNTech, Moderna, eTheRNA, and Onkaido have advanced the preclinical and clinical development of mRNA-based therapeutics. Hence, growing academic and industrial interest in mRNA technology is anticipated to increase the need for mRNA synthesis raw materials, thereby boosting market growth.

Furthermore, the simplicity to manufacture the mRNA vaccine is a key reason for the development of these vaccines. For instance, it is essential for DNA to enter the nucleus, and then it can be transcribed into mRNA. However, mRNA does not need to enter the nucleus to function as it initiates protein translation in the cytoplasm. Hence, this process makes the mRNA vaccine more efficient and simple to manufacture. In contrast to viral vectors and DNA, mRNAs do not insert into the genome but express the encoded protein instantaneously. Typical cellular processes can eliminate the mRNA since it doesn’t integrate into the host genome, thus eliminating any chance of infection or insertion mutation. In addition, the In Vitro Transcription (IVT) process readily synthesizes mRNA. The process is relatively inexpensive and can be quickly applied to a variety of therapies. Such advantages of mRNA vaccines are anticipated to drive the market during the study period.

Moreover, several operating players in the market and various research institutes are receiving funding for the development of novel mRNA therapeutics. For instance, in October 2022, the University of Columbia received USD 11.1 million in funding from the government of Canada to advance the mRNA vaccine technology. This funding aims to improve their efficacy, reduce the potential side effects of vaccines, and allow for a smaller vaccine dosage. Similarly, in December 2022, ExPLoRNA Therapeutics received USD 813,578 in funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology. Therefore, rising funding for research is expected to increase the need for mRNA synthesis raw materials and fuel the market growth during the forecast period.

Additionally, the growing prevalence of chronic and infectious diseases is increasing the therapeutic application of mRNA technology. For instance, according to WHO, cancer is one of the leading causes of death worldwide, causing almost one in six deaths, while cardiovascular diseases lead to an estimated 17.9 million deaths each year. In addition, according to WHO, about 10 million people worldwide contracted tuberculosis in 2020 (1.1 million children, 5.6 million men, & 3.3 million women). Hence, scientists in industries and universities worldwide are finding novel and innovative ways to develop therapeutics using mRNA technology to prevent and treat disease. For instance, researchers at Penn Medicine are using the mRNA platform to create vaccines for several conditions such as cancer, treatment for food and environmental allergies, genetic diseases, and heart attack and stroke, among others.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global recombinant DNA technology market size was valued at USD 728.9 billion in 2023 and is projected to grow at a CAGR of 5.4% from 2024 to 2030.

• The global DNA diagnostics market size was estimated at USD 10.64 billion in 2023 and is projected to grow at a CAGR of 4.51% from 2024 to 2030.

Key mRNA Synthesis Raw Materials Company Insights

The market players operating in the mRNA synthesis raw materials market are adopting product approval to increase the reach of their products in the market and improve the availability of their products in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key mRNA Synthesis Raw Materials Companies:

The following are the leading companies in the mRNA synthesis raw materials market. These companies collectively hold the largest market share and dictate industry trends

·         F. Hoffmann-La Roche Ltd.

·         Jena Bioscience GmbH

·         Merck KGaA

·         Yeasen Biotechnology (Shanghai) Co., Ltd.

·         BOC Sciences

·         Thermo Fisher Scientific, Inc.

·         Maravai LifeSciences

·         New England Biolabs

·         Creative Biogene

·         HONGENE

Recent Developments

In April 2024, Telesis Bio Inc. announced its refocusing strategy to promote its innovative Gibson SOLA platform, targeting DNA and mRNA drug discovery. The company will also concentrate on enhancing its BioXp platform for mRNA synthesis, leveraging its distinct competitive advantage.

In February 2023, Life Edit Therapeutics Inc. and Moderna Inc. signed a collaboration agreement to discover and develop mRNA gene-editing therapies.

In January 2023, BioNTech and the UK Government signed a Strategic Partnership Agreement to help patients by advancing clinical trials for targeted mRNA immune therapies. To provide targeted cancer therapies to up to 10,000 patients by the end of 2030, through clinical trials or as approved treatments

Order a free sample PDF of the MRNA Synthesis Raw Materials Market Intelligence Study, published by Grand View Research.